Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Potential of Naturally Occurring Mucoadhesive Polymer in Vaginal Infection


Affiliations
1 School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India
     

   Subscribe/Renew Journal


Mucoadhesive formulations, which bind to the vaginal mucosa and play a significant role in drug release, are now being used for controlled release. The vagina is a significant area of the reproductive tract and helps as a potential route of drug administration. it is also of importance for systemic drug delivery, and uterine targeting. Currently, available dosage forms have several limitations, therefore novel concepts and dosage forms are needed. In this field, mucoadhesive polymers will play a major role. This review highlights the most important studies based on mucoadhesive polymer-systems like poly (acrylates), hyaluronic acid derivatives, pectin, chitosan, cellulose derivatives, tragacanth sulfated polysaccharides, carrageenan, Na-alginate, starch, poly (ethylene glycol), and gelatin.

Keywords

Mucoadhesive, Controlled Release, Vaginal Infection, Mucoadhesion
Subscription Login to verify subscription
User
Notifications
Font Size


  • Chore MSA, Dighade SJ. A Review on Mucoadhesive Vaginal Drug Delivery System. Int J Reserach Pharm Chem. 2020;10(4):350–64.

  • Boddupalli BM. Mucoadhesive drug delivery system: An overview. J Adv Pharm Tech Res. 2010;(October):2–8.

  • Sharma M, Sheeba FR, Yadav RP, Patel AK, Kumar Y. Mucoadhesive polymers for buccal drug delivery system: An overview. Asian J Pharm Res Dev. 2021;9(2):57–64.

  • Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery—a promising option for orally less efficient drugs. J Control release. 2006;114(1):15–40.

  • Sahin HT, Arslan MB. A study on physical and chemical properties of cellulose paper immersed in various solvent mixtures. Int J Mol Sci. 2008;9(1):78–88.

  • Baumgartner S, Kristl J, Peppas NA. Network structure of cellulose ethers used in pharmaceutical applications during swelling and at equilibrium. Pharm Res. 2002;19(8):1084–90.

  • Furst T, Piette M, Lechanteur A, Evrard B, Piel G. Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application. Eur J Pharm Biopharm. 2015;95:128–35.

  • Yadav VK, Gupta AB, Kumar R, Yadav JS, Kumar B. Mucoadhesive polymers: means of improving the mucoadhesive properties of drug delivery system. J Chem Pharm Res. 2010;2(5):418–32.

  • Mohnen D. Pectin structure and biosynthesis. Curr Opin Plant Biol. 2008;11(3):266–77.

  • Round AN, Rigby NM, MacDougall AJ, Morris VJ. A new view of pectin structure revealed by acid hydrolysis and atomic force microscopy. Carbohydr Res. 2010;345(4):487–97.

  • Willats WGT, Knox JP, Mikkelsen JD. Pectin: new insights into an old polymer are starting to gel. Trends Food Sci Technol. 2006;17(3):97–104.

  • Klemetsrud T, Jonassen H, Hiorth M, Kjøniksen A-L, Smistad G. Studies on pectin-coated liposomes and their interaction with mucin. Colloids Surfaces B Biointerfaces. 2013;103:158–65.

  • Zhu F. Composition, structure, physicochemical properties, and modifications of cassava starch. Carbohydr Polym. 2015;122:456–80.

  • Wu AC, Li E, Gilbert RG. Exploring extraction/dissolution procedures for analysis of starch chain-length distributions. Carbohydr Polym. 2014;114:36–42.

  • Tester RF, Karkalas J, Qi X. Starch—composition, fine structure and architecture. J Cereal Sci. 2004;39(2):151–65.

  • Mehta S, Verstraelen H, Vandaele L, Mehuys E, Remon JP, Vervaet C. Vaginal distribution and retention of tablets comprising starch-based multiparticulates: Evaluation by colposcopy. Drug Dev Ind Pharm. 2013;39(12):1944–50.

  • Poelvoorde N, Verstraelen H, Verhelst R, Saerens B, De Backer E, dos Santos Santiago GL, et al. In vivo evaluation of the vaginal distribution and retention of a multi-particulate pellet formulation. Eur J Pharm Biopharm. 2009;73(2):280–4.

  • Gacesa P. Alginates. Carbohydr Polym. 1988;8(3):161–82.

  • Sutherland IW. Alginates. In: Biomaterials. Springer; 1991. p. 307–31.

  • Poncelet D, Babak V, Dulieu C, Picot A. A physico-chemical approach to production of alginate beads by emulsification-internal ionotropic gelation. Colloids Surfaces A Physicochem Eng Asp. 1999;155(2–3):171–6.

  • Ching SH, Bansal N, Bhandari B. Alginate gel particles–A review of production techniques and physical properties. Crit Rev Food Sci Nutr. 2017;57(6):1133–52.

  • Al Sagheer FA, Al-Sughayer MA, Muslim S, Elsabee MZ. Extraction and characterization of chitin and chitosan from marine sources in Arabian Gulf. Carbohydr Polym. 2009;77(2):410–9.

  • Islam S, Bhuiyan MAR, Islam MN. Chitin and chitosan: structure, properties and applications in biomedical engineering. J Polym Environ. 2017;25(3):854–66.

  • Pillai CKS, Paul W, Sharma CP. Chitin and chitosan polymers: Chemistry, solubility and fiber formation. Prog Polym Sci. 2009;34(7):641–78.

  • Ravindra R, Krovvidi KR, Khan AA. Solubility parameter of chitin and chitosan. Carbohydr Polym. 1998;36(2–3):121–7.

  • Riva R, Ragelle H, des Rieux A, Duhem N, Jérôme C, Préat V. Chitosan and chitosan derivatives in drug delivery and tissue engineering. Chitosan Biomater II. 2011;19–44.

  • Osmałek T, Froelich A, Jadach B, Tatarek A, Gadziński P, Falana A, et al. Recent Advances in Polymer-Based Vaginal Drug Delivery Systems. Pharmaceutics. 2021;13(6):884.

  • Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010;56(3):290–9.

  • Zhang H, Tao Y, Guo J, Hu Y, Su Z. Hypolipidemic effects of chitosan nanoparticles in hyperlipidemia rats induced by high fat diet. Int Immunopharmacol. 2011;11(4):457–61.

  • Lupo N, Fodor B, Muhammad I, Yaqoob M, Matuszczak B, Bernkop-Schnürch A. Entirely S-protected chitosan: A promising mucoadhesive excipient for metronidazole vaginal tablets. Acta Biomater. 2017;64:106–15.

  • Garcıa-Ochoa F, Santos VE, Casas JA, Gómez E. Xanthan gum: production, recovery, and properties. Biotechnol Adv. 2000;18(7):549–79.

  • Rosalam S, England R. Review of xanthan gum production from unmodified starches by Xanthomonas comprestris sp. Enzyme Microb Technol. 2006;39(2):197–207.

  • Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control release. 2005;109(1–3):256–74.

  • Yavuz ST, Sahiner UM, Sekerel BE, Tuncer A, Kalayci O, Sackesen C. Anaphylactic reactions to measles–mumps–rubella vaccine in three children with allergies to hen’s egg and cow’s milk. Acta Paediatr. 2011;100(8):e94–6.

  • Singla AK, Chawla M. Chitosan: Some pharmaceutical and biological aspects‐an update. J Pharm Pharmacol. 2001;53(8):1047–67.

  • Ilium L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15(9):1326–31.

  • Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technolo Today. 1998;1(6):246–53.

  • Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev. 1995;16(1):45–50.

  • Nigalaye AG, Adusumilli P, Bolton S. Investigation of prolonged drug release from matrix formulations of chitosan. Drug Dev Ind Pharm. 1990;16(3):449–67.

  • Lee JW, Park JH, Robinson JR. Bioadhesive‐based dosage forms: The next generation. J Pharm Sci. 2000;89(7):850–66.

  • Lanchares JL, Hernandez ML. Recurrent vaginal candidiasis, changes in etiopathogenical patterns. Int J Gynecol Obstet. 2000;71(Suppl. 1).

  • Ferrer J. Vaginal candidosis: epidemiological and etiological factors. Int J Gynecol Obstet. 2000;71:21–7.

  • Bernkop-Schnürch A, Hornof M, Zoidl T. Thiolated polymers—thiomers: synthesis and in vitro evaluation of chitosan–2-iminothiolane conjugates. Int J Pharm. 2003;260(2):229–37.

  • El-Kamel AH, Sokar MS, Naggar VF, Al-Gamal SS. Bioadhesive controlled release metronidazole vaginal tablets. ACTA Pharm. 2002;52(3):171–80.

  • Ceschel GC, Maffei P, Borgia SL, Ronchi C, Rossi S. Development of a mucoadhesive dosage form for vaginal administration. Drug Dev Ind Pharm. 2001;27(6):541–7.

  • Richardson JL, Armstrong TI. Vaginal delivery of calcitonin by hyaluronic acid formulations. Drugs Pharm Sci. 1999;98:563–99.

  • Richardson JL, Ramires PA, Miglietta MR, Rochira M, Bacelle L, Callegaro L, et al. Novel vaginal delivery systems for calcitonin: I. Evaluation of HYAFF/calcitonin microspheres in rats. Int J Pharm. 1995;115(1):9–15.

  • Bonucci E, Ballanti P, Ramires PA, Richardson JL, Benedetti LM. Prevention of ovariectomy osteopenia in rats after vaginal administration of Hyaff 11 microspheres containing salmon calcitonin. Calcif Tissue Int. 1995;56(4):274–9.

  • Patel GM, Patel MM. Vagina: An ideal site for drug delivery. Res J Pharm Technol. 2009;2(3):426–32.

  • Bombart F. Aqueous vaginal douche compositions. WO. 1992;9210998:A1.

  • Baloğlu E, Özyazıcı M, Hızarcıoğlu SY, Karavana HA. An in vitro investigation for vaginal bioadhesive formulations: bioadhesive properties and swelling states of polymer mixtures. Farm. 2003;58(5):391–6.

  • Graham NB, McNeill ME. Hydrogels for controlled drug delivery. Biomaterials. 1984;5(1):27–36.

  • Embrey MP, Graham NB, McNeill ME, Hillier K. In vitro release characteristics and long term stability of poly (ethylene oxide) hydrogel vaginal pessaries containing prostaglandin E2. J Control release. 1986;3(1–4):39–45.

  • Owen DH, Dunmire EN, Plenys AM, Katz DF. Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus. J Control release. 1999;60(1):23–34.

  • Richardson JL, Illum L. VIII: the vaginal route of peptide and protein drug delivery. Adv Drug Deliv Rev. 1992;8(2–3):341–66.

  • Richardson JL, Illum L, Thomas NW. Vaginal absorption of insulin in the rat: effect of penetration enhancers on insulin uptake and mucosal histology. Pharm Res. 1992;9(7):878–83.

  • Digenis GA, Nosek D, Mohammadi F, Darwazeh NB, Anwar HS, Zavos PM. Novel vaginal controlled-delivery systems incorporating coprecipitates of nonoxynol-9. Pharm Dev Technol. 1999;4(3):421–30.

  • Meignant C, Vieillard-Baron C, Verdier S. Synergistic pharmaceutical combination containing imidazole derivatives for locally treating vulvovaginitis and vaginosis. WO; 1999.

  • Dunmire EN, Katz DF. Alteration of human sperm kinematics in cervical mucus due to nonoxynol-9. Contraception. 1997;55(4):209–17.


Abstract Views: 143

PDF Views: 0




  • Potential of Naturally Occurring Mucoadhesive Polymer in Vaginal Infection

Abstract Views: 143  |  PDF Views: 0

Authors

Ishwar Singh
School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India
Jatin Sharma
School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India
Inder Kumar
School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India
Shivali Singla
School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India
Amit Chaudhary
School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India
Sunny Dhiman
School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, HP, India

Abstract


Mucoadhesive formulations, which bind to the vaginal mucosa and play a significant role in drug release, are now being used for controlled release. The vagina is a significant area of the reproductive tract and helps as a potential route of drug administration. it is also of importance for systemic drug delivery, and uterine targeting. Currently, available dosage forms have several limitations, therefore novel concepts and dosage forms are needed. In this field, mucoadhesive polymers will play a major role. This review highlights the most important studies based on mucoadhesive polymer-systems like poly (acrylates), hyaluronic acid derivatives, pectin, chitosan, cellulose derivatives, tragacanth sulfated polysaccharides, carrageenan, Na-alginate, starch, poly (ethylene glycol), and gelatin.

Keywords


Mucoadhesive, Controlled Release, Vaginal Infection, Mucoadhesion

References